Finance News World

Diabetic Peripheral Neuropathy Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Diabetic Peripheral Neuropathy Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 18
12:44 2020
Diabetic Peripheral Neuropathy Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 

 

DelveInsight has launched a new report on CDiabetic Peripheral Neuropathy Market Insights, Epidemiology and Pipeline Insight, 2020.

“Diabetic Peripheral Neuropathy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided, which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces in-depth Diabetic Peripheral Neuropathy commercial assessment and clinical assessment of the Diabetic Peripheral Neuropathy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease. It is common prevalent complication in neurological damage of Type 1 and Type 2 diabetes. Main risk factors contributing to DSPN are smoking, obesity, hyperlipidemia, duration of diabetes, large total exposure to hyperglycemia, advanced age, elevated lipid levels, elevated blood pressure, kidney disease, cigarette smoking, overweight, increased height, and others.
 
The signs and symptoms of DPN include numbness, tingling, poor balance, burning pain, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others.Diagnosis of DSPN includes the screening, assessment, quantitative sensory testing, nerve conduction studies, novel surrogate imaging markers of DPN, biopsy for skin and nerve fiver, optical coherence tomography and others.  Management and prevention of the DSPN generally includes glycemic control, lifestyle modification, pathogenetic therapies and pain management by using the various pharmaceutical intervention.
 
 
 
 
 
Diabetic Peripheral Neuropathy of Pipeline Development activities:- 

The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Diabetic Peripheral Neuropathy with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Diabetic Peripheral Neuropathy treatment.
  • Diabetic Peripheral Neuropathy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Diabetic Peripheral Neuropathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  

 
Report Key Facts:- 
 
1. According to DelveInsight estimates,total diagnosed prevalent population of Diabetic Peripheral Neuropathy in 7MM was found to be 25,332,829 in 2017.
 
2. Among the EU5 countries, Germany has the highest prevalent cases with 3,904,730 cases in 2017, followed by Italy while UK on the other hand had the lowest cases, whereas Japan had 3,243,016 cases of DPN in 2017.
 
 
Diabetic Peripheral Neuropathy Analytical Perspective by DelveInsight

  • In-depth Diabetic Peripheral Neuropathy Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Diabetic Peripheral Neuropathy Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

 

“According to DelveInsight’s analysis, about 3,756,745 cases of painful DPN in the US in 2017” 

 
Key major companies working on Diabetic Peripheral Neuropathy that are given below-
1. Helixmith
2. Aptinyx
3. WinSanTor
4. Regenacy Pharmaceuticals
 
Drugs covered are given below-
1. VM202
2. NYX-2925
3. WST-057
4. Ricolinostat
 
 

1. Report Introduction

2. Diabetic Peripheral Neuropath

3. Diabetic Peripheral Neuropathy Current Treatment Patterns

4. Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diabetic Peripheral Neuropathy Late Stage Products (Phase-III)

7. Diabetic Peripheral Neuropathy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diabetic Peripheral Neuropathy Discontinued Products

13. Diabetic Peripheral Neuropathy Product Profiles

14. Diabetic Peripheral Neuropathy Key Companies

15. Diabetic Peripheral Neuropathy Key Products

16. Dormant and Discontinued Products

17. Diabetic Peripheral Neuropathy Unmet Needs

18. Diabetic Peripheral Neuropathy Future Perspectives

19. Diabetic Peripheral Neuropathy Analyst Review  

20. Appendix

21. Report Methodology

22. About Delveinsight

 

Scope of the report

  • The Diabetic Peripheral Neuropathy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Diabetic Peripheral Neuropathy across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Diabetic Peripheral Neuropathy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Diabetic Peripheral Neuropathy research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Diabetic Peripheral Neuropathy.
 
Related Reports:- 
 
 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/